Novo Holdings’ early-stage investment and company creation team Novo Seeds has established a new portfolio company – Hemab – which will focus on the development of bispecific antibodies for rare bleeding disorders.
The company, co-founded by former Novo Nordisk executives Johan Faber and Søren Bjørn, has secured an exclusive license to certain intellectual property to develop a product within haemophilia and other rare bleeding disorders from Novo Nordisk.
Hemab has also scored an exclusive license to Genmab’s bispecific DuoBody platform technology, which will help the company to develop further novel therapies for ultra-rare bleeding disorders.
“We are very pleased to have Novo Seeds on board as investor and partner to accelerate the development of our exciting new technology platform,” said Johan Faber, co-founder and chief executive officer of Hemab.
“We are passionate about developing novel therapies for people with severe bleeding disorders that are in high need for a prophylactic treatment option that is effective, safe and convenient. With the hands-on support of Novo Seeds we have a strong foundation to realize our ambitions for patients with rare bleeding disorders,” he added.
Jørgen Søberg Petersen, Novo Seeds Partner, will join Henmab as chairman and Camilla Petrycer Hansen, Novo Seeds Senior Associate, will also join the board.
In addition, Benny Sørensen, will join the board as an independent non-executive director.
Sørensen currently serves as senior vice president, head of clinical development at Codiak BioSciences.
by Lucy Parsons
Source: pharmatimes.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.